Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-23
DOI
10.1007/s00280-021-04249-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies
- (2020) Mohamed Elmeliegy et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer
- (2020) Ignacio Duran et al. CLINICAL PHARMACOKINETICS
- TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Neeraj Agarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).
- (2020) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
- (2020) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
- (2019) Noel W. Clarke et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.
- (2019) Matthew Raymond Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Advanced Prostate Cancer
- (2019) Min Yuen Teo et al. Annual Review of Medicine
- A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
- (2019) Floor J. E. Lubberman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
- (2019) Anita Gul et al. Cancer Management and Research
- LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
- (2019) K Fizazi et al. ANNALS OF ONCOLOGY
- The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer
- (2018) Kathleen Moore et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer
- (2018) Bodine P. S. I. Belderbos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
- (2018) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer
- (2017) Neal Shore et al. UROLOGY
- Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
- (2017) Mohammad Asim et al. Nature Communications
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
- (2013) W. R. Polkinghorn et al. Cancer Discovery
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Roles of PARP-1 Promote Cancer Growth and Progression
- (2012) M. J. Schiewer et al. Cancer Discovery
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started